REPLIGEN CORP Debt Instrument, Convertible, Carrying Amount of Equity Component
REPLIGEN CORP (RGEN) had Debt Instrument, Convertible, Carrying Amount of Equity Component of $39.07 million as of 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent · last filed 2020-05-06
- 2020-03-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $39.07M.
- 2019-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $39.07M.
- 2019-09-30: Debt Instrument, Convertible, Carrying Amount of Equity Component $38.09M.
| Period end | Debt Instrument, Convertible, Carrying Amount of Equity Component |
|---|---|
| 2020-03-31 | $39.07M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $39.07M 10-Q · filed 2020-05-06 |
| 2019-09-30 | $38.09M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |